Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking a significant advancement in the treatment of neurodegenerative diseases. This collaboration focuses on the development of COYA 302, a dual biologic designed to combat neuroinflammation and treat various neurodegenerative conditions.

COYA 302: A Dual Biologic with Promising Potential

The COYA 302 therapy combines two components, COYA 301 and CTLA4-Ig. Under this agreement, Coya Therapeutics will develop COYA 301 and in-license Dr. Reddy’s proposed biosimilar Abatacept for the development and commercialization of COYA 302. This innovative therapy aims to suppress neuroinflammation through multiple immunomodulatory pathways, offering a new approach to managing neurodegenerative diseases.

Expanding Reach in Neurodegenerative Disease Treatment

Coya Therapeutics has been granted an exclusive, royalty-bearing license to Dr. Reddy’s biosimilar Abatacept for the development of COYA 302. The agreement spans multiple territories, including North and South America, the EU, United Kingdom, and Japan. This partnership extends Coya’s reach in developing and commercializing treatments for neurological diseases, with Dr. Reddy’s also obtaining rights to commercialize COYA 302 in areas outside of Coya’s territory.

A Step Forward in Clinical Development

Coya Therapeutics anticipates filing an Investigational New Drug (IND) application for COYA 302 in the second half of 2023, aiming to initiate a phase 1b/2 trial in Amyotrophic Lateral Sclerosis (ALS) soon after. This marks a crucial step in bringing this potential treatment to clinical trials, addressing critical unmet needs in neurodegenerative disease care.

Leveraging Scientific Capabilities and Product Portfolio

The collaboration leverages the scientific capabilities and product portfolio of both organizations. Dr. Jayanth Sridhar, Global Head of Biologics at Dr. Reddy’s, expressed enthusiasm for collaborating with Coya in advancing therapies for neurodegenerative diseases. This partnership represents a fusion of biotechnological expertise and a commitment to addressing complex health challenges.

Pioneering a New Treatment Approach

Coya Therapeutics and Dr. Reddy’s joint efforts in developing COYA 302 highlight the potential of biotechnology in transforming treatment approaches for neurodegenerative diseases. The innovative combination therapy approach targets chronic inflammation, a key driver in the progression of such diseases. With preliminary data showing promise, this collaboration could lead to significant breakthroughs in medical treatment for conditions like ALS.

  COYA 302, Coya Therapeutics, Dr Jayanth Sridhar, Dr. Reddy’s Laboratories